BCL2 and plasma cell myeloma: The inhibitors of BCL2 show efficacy in pre-clinical and early phase clinical trials of myeloma [31], small-cell-lung cancer [32], high-risk B cell non-Hodgkin lymphoma, and leukemia [26–27, 33–34].